-
1
المؤلفون: Claudia Bejar, Eve Maubec
المصدر: Current Treatment Options in Oncology. 15:302-320
مصطلحات موضوعية: Skin Neoplasms, medicine.medical_treatment, Calcineurin Inhibitors, Administration, Oral, Alpha interferon, Antineoplastic Agents, Targeted therapy, Recurrence, medicine, Humans, Pharmacology (medical), Epidermal growth factor receptor, Cell Proliferation, EGFR inhibitors, Immunosuppression Therapy, biology, Squamous Cell Carcinoma of Head and Neck, business.industry, Immunosuppression, Immunotherapy, Prognosis, ErbB Receptors, Calcineurin, stomatognathic diseases, Treatment Outcome, Oncology, Head and Neck Neoplasms, Sirolimus, Mutation, Immunology, Carcinoma, Squamous Cell, Cancer research, biology.protein, Cisplatin, business, Immunosuppressive Agents, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e32e203cb36c3af00ceedfb47fd9ce40Test
https://doi.org/10.1007/s11864-014-0280-xTest -
2
المؤلفون: Megan Kokon, Sara Shafqat, John F. Deeken, Timothy L. Cannon
المصدر: Current treatment options in oncology. 16(7)
مصطلحات موضوعية: Neuroblastoma RAS viral oncogene homolog, Oncology, medicine.medical_specialty, Bevacizumab, Colorectal cancer, medicine.medical_treatment, Antineoplastic Agents, medicine.disease_cause, Disease-Free Survival, Targeted therapy, Proto-Oncogene Proteins p21(ras), Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Panitumumab, Humans, Pharmacology (medical), Molecular Targeted Therapy, EGFR inhibitors, Randomized Controlled Trials as Topic, Cetuximab, business.industry, Antibodies, Monoclonal, Exons, medicine.disease, ErbB Receptors, Treatment Outcome, Mutation, KRAS, business, Colorectal Neoplasms, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32d88a54cf32f81788894c43ac927056Test
https://pubmed.ncbi.nlm.nih.gov/26050230Test -
3
المؤلفون: Leora Horn, Christine M. Lovly
المصدر: Current treatment options in oncology. 13(4)
مصطلحات موضوعية: Oncology, medicine.medical_specialty, Lung Neoplasms, Afatinib, non-small cell lung cancer (NSCLC), Antineoplastic Agents, Disease-Free Survival, chemistry.chemical_compound, T790M, Erlotinib Hydrochloride, Gefitinib, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Pharmacology (medical), Progression-free survival, Protein Kinase Inhibitors, EGFR inhibitors, business.industry, medicine.disease, Dacomitinib, respiratory tract diseases, ErbB Receptors, Treatment Outcome, chemistry, Drug Resistance, Neoplasm, Immunology, Mutation, Quinazolines, Erlotinib, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f55683424dc4d4df7c837d6f3adc1e5Test
https://pubmed.ncbi.nlm.nih.gov/22833206Test